Noninvasive imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain in vivo is critical for elucidating the role of these receptors in normal brain function and in the pathogenesis of brain disorders. Here we report the first in vivo visualization of human brain areas containing nAChRs by using PET and 2-[
The two most abundant subtypes of nAChRs in mammalian brain are those containing α4 and β2 subunits and those containing α7 subunits (1) . Among nAChRs, those containing α4 and β2 subunits, and probably those subtypes containing β2 in combination with other subunits, have the highest affinity for nicotine (2) , an addicting ingredient of tobacco smoke (3) . Therefore, these receptors are most likely the primary targets for nicotine in the brain. Furthermore, in mice these receptors are necessary for this alkaloid to produce its reinforcing, rewarding, and antinociceptive effects (3) (4) (5) (6) (7) (8) . The densities of nAChRs with high affinity for nicotinic agonists are greater in postmortem brain tissues from smokers than from nonsmokers and ex-smokers (9) (10) (11) . In addition, these nAChRs are affected in a variety of neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease (1, (12) (13) (14) (15) (16) .
To date, [ 11 C]nicotine is the only nAChR radioligand used for PET studies in humans (17) (18) (19) (20) . Unfortunately, this ligand has a number of drawbacks, such as rapid dissociation of the receptorligand complex, high non-specific binding, and a strong dependency of its cerebral accumulation on cerebral blood flow (21) (22) (23) . Although modeling approaches have been developed to improve the analysis of PET data obtained by using [ 11 C]nicotine (18, 21) , it continues to be a suboptimal radioligand for imaging brain nAChRs.
In 1996, a new ligand, 3-(2(S)-azetidinylmethoxy)pyridine (A-85380), which has high affinity and selectivity for the α4β2 subtype of nAChRs, was identified as a lead compound for development of new pharmaceuticals targeting nAChRs (24) . With the goal of developing radioligands suitable for imaging nAChRs in humans with PET, we synthesized several halogenated analogs of A-85380 (25) . Several ligands from this series, including 2-fluoro-3-((S)-2-azetidinylmethoxy)pyridine, also had high affinity and selectivity for the α4β2 and probably other β2 containing subtypes of nAChRs, having K i values in the low picomolar range (25) . In 1998, the radiosynthesis of 2-[
18 F]fluoro-3-((S)-2-azetidinylmethoxy)pyridine, commonly known as 2-[
18 F]F-A85380 (2-[ 18 F]FA) was described (26) (27) (28) . As favorable preclinical imaging (29) (30) (31) (32) (33) and toxicology data (27, 34) have been obtained, the current study aimed to determine whether 2-[
18 F]FA could be used to image nAChRs in human brain with PET within radiation dose limits and to confirm the safety of the no-carrier-added radiolabeled drug. Also presented are data from non-human primate studies demonstrating that 2-[
18 F]FA accumulation in brain represents binding to nAChRs.
MATERIALS AND METHODS

Radiochemistry
The radiolabeled drug product 2-[
18 F]FA injection, prepared by a semi-automated modification of the method described previously (27) , was formulated as a sterile, apyrogenic solution in saline. The specific activity of 2-[ 18 F]FA at the end-of-synthesis was in range of 215 to 1400 GBq/µmol (5.8-37.0 Ci/µmol) and the radiochemical purity was >98%. Specific activity at the time of administration ranged from 210 to 1100 GBq/µmol (5.6 to 30.0 Ci/µmol). The chemical purity of 2-[
18 F]FA was determined by thin layer chromatography (Kryptofix 222 < 500 µg/batch) and by gas chromatography (methanol, ethanol, and acetonitrile <5 mg/batch per solvent).
Human studies
Research Participants
Three male and three female healthy volunteers (three African-American, ages 25, 26, and 37; and three Caucasian, ages 28, 30, and 45) were recruited through newspaper advertisements. Inclusionary criteria were age between 21 and 45 years, and IQ >80 (assessed by the Shipley Institute of Living Scale) (35) . Exclusionary criteria were current psychopathology [SCL-90 (36)], history of psychiatric disorders by DSM-IV criteria [Diagnostic Interview Schedule for DSM-IV (DIS-IV) (37)], current tobacco use (within previous 6 mo), drug abuse history, and evidence of acute or chronic medical problems (as assessed by medical history, physical examination, and routine blood screen). All participants gave written informed consent after receiving an explanation of the study and its procedures. The Institutional Review Boards of National Institute on Drug Abuse (NIDA) Intramural Research Program and the Johns Hopkins Bayview Medical Center approved the design of this study. Administration of the radioligand to the human volunteers was performed under an Investigational New Drug (IND) application to the Food and Drug Administration (FDA).
Study design
The research participants stayed in a research study room at NIDA for 24 h prior to and 24 h after the PET study. Baseline blood chemistry and hematology were obtained 24 h prior to the study and baseline cardiovascular measures were obtained twice, 2 h and 24 h prior to the study.
To ensure that adequate data were collected to assess the contribution of the various organs to the overall radiation dosimetry, three scanning procedures were used. In all procedures, the PET session commenced with the bolus injection of ca. 1.6 MBq/kg (0.043 mCi/kg) of 2-[
18 F]FA. For scanning procedure 1, three sets of whole-body PET scans from the top of the head to mid-thigh were obtained in two participants (one male, one female). The time required for each of these whole-body acquisitions ranged from 1.5 to 2.5 h. This procedure surveyed all of the internal organs and allowed us to verify our assumption that the urinary bladder, kidneys, and liver were the organs receiving the greatest radiation dose. Each scan set contained 8 to 9 overlapping 15.5 cm fields of view, which surveyed the body from the top of the head to mid-thigh. Transmission scans were obtained at each position to correct for photon attenuation by bone and soft tissue.
In scanning procedure 2, scan sets contained 4 to 5 overlapping 15.5-cm fields of view covering organs from the top of the liver to the testes (male) or bottom of the bladder wall (female). This procedure was used for three additional participants (2 females, 1 male). With this procedure, we obtained the time course of the radioactivity in the organs that were expected to receive the greatest radiation dose. Transmission scans were obtained at each position to correct for photon attenuation by bone and soft tissue.
In addition to the brain scans acquired on the two subjects by using scanning procedure 1, the distribution of the radioligand in the brain was acquired at 11 time points in a 6th participant (male). This scanning procedure alternated between acquiring scans of the brain and the urinary bladder and added data on visualizing nAChRs in the brain while also obtaining time course data on the urinary bladder, which was expected to receive the greatest radiation dose. For all procedures, we attempted to place arterial catheters. When attempts at placing the arterial catheters failed, venous lines were used for the collection of blood samples instead.
At predetermined intervals starting immediately after the 2-[
18 F]FA injection to 1 h postinjection, all participants were asked whether they felt a drug effect. Heart rate, blood pressure, respiratory rate, and ECG parameters were monitored at predetermined intervals throughout the 7-h scanning period. During the scans, when the participants were not answering questions, they rested quietly, slept, or watched videotaped movies for entertainment. The concentration of radioactivity was measured in 18-20 venous blood samples (in four participants) and twenty arterial samples (in two participants) that were collected at predetermined intervals from immediately after the injection until 7 h after the injection. Using urine voids collected from all six subjects for 24 h after the injection of the radioligand, the volume and concentration of radioactivity were measured. These data were used to calculate the residence time for the urinary bladder contents.
PET scans were performed on a Siemens ECAT Exact HR+. This instrument produces images of 63 contiguous transaxial slices, with a 15.5-cm field of view, and a 4.6-mm transaxial resolution. A thermoplastic facemask, custom-made for each subject, was used to minimize head movement and was worn by three participants while data was acquired from their brains, but removed during acquisition of data from other organs. Scan data were reconstructed with attenuation correction.
Structural MRI scans were obtained for the three participants from whom cerebral PET scans were acquired. For each subject, 124 transaxial T1-weighted slices were obtained parallel to the AC-PC line on a General Electric Signa (1.5T) scanner.
Data analysis
Brain Image Analysis: Brain imaging data from all brain scans were reconstructed by using a HANN filter to reduce high-frequency noise (38) . PET data for each subject were co-registered to the structural MRI by using the normalized mutual information registration algorithm in Analyze AVW (v. 4.0). The coregistered PET and structural MRI images for each subject were used to identify the location of the accumulated radioactivity in the brain. Images were prepared for analysis and display by using MEDx (v. 3.4) and Analyze AVW (v. 4.0).
Radiation doses to the various organs were estimated by MIRDOSE (v. 3.1) (39). The organ residence times were calculated as the area under the time activity curves, with the assumption that at the time points exceeding the scanning period, the organ radioactivity was dependent only on the physical decay of radionuclide. The residence time for the urinary bladder contents was calculated by using a dynamic bladder model (MIRDOSE (v. 3.1) (39) based on the accumulation of radioactivity in urine.
Non-human primate studies
The Animal Care and Use Committee (ACUC) of the NIDA Intramural Research Program approved all animal research experiments. Two adult male Rhesus monkeys, (Macaca mulatta, 7 and 10 kg) were used in PET studies designed to confirm the specificity of radioligand binding. Animals were prepared for the PET studies as described previously (29) . Briefly, monkeys were initially anesthetized by an i.m. injection of 1.5 mg/kg alfadolone and alfaxolone acetate (Saffan ® , Arnolds Veterinary Products, Shropshire, UK). Anesthesia was maintained throughout the study by a continuous intravenous infusion of 9-14 mg/kg/h Saffan. To reproducibly position the monkeys' heads between studies, each monkey was fitted with an individually molded thermoplastic facemask. The monkey's head was positioned in the scanner gantry with the aid of orthogonal laser lines to ensure that the whole brain was in the field of view. 18 F]FA injection and continuing for the duration of PET scanning. A second monkey participated in a control study and one in which nicotine was continuously infused as described. Data were acquired on a Siemens ECAT Exact HR+ whole-body tomograph in 3-D mode. Before each radioligand administration, transmission scans were acquired to correct the emission scans for signal attenuation by bone and soft tissue. PET images were reconstructed from the raw data with a standard filtered-back projection algorithm and a RAMP filter.
RESULTS and DISCUSSION
Visualizing nAChRs in the brain
The total accumulation of radioactivity in the human brain reached a maximum of 2.5 ± 0.2% of the injected dose (ID) between 50 and 80 min after 2-[
18 F]FA administration. The greatest accumulation of radioactivity was observed in the thalamus, midbrain, and pons, consistent with moderate-to-high densities of nAChRs in these regions (Fig. 1) . With the administered dose of radioligand, visualization of the radioactivity in these brain regions was possible for up to 5 h after the injection. The accumulation of radioactivity in the thalamus was relatively homogeneous. Activity in the midbrain could not be unambiguously assigned to specific nuclei, but probably represents binding to nAChRs in the tegmental area, periaqueductal gray, red nucleus, and substantia nigra, all of which contain moderate-to-high densities of nAChRs, according to postmortem studies (40) . In contrast to all other studied regions, the cerebellum and pons exhibited greater accumulation of radioactivity (normalized to administered dose per kilogram of body weight) in the human brain vs. that observed in the Rhesus monkey brain (29 (29, 42, 43) , the receptor binding of both of these radioligands in the baboon cerebellum was more pronounced (32, 44) . These findings suggest that the differences in the distribution patterns are species-related.
Previous in vitro and in vivo studies in rodents demonstrated that 2FA specifically binds to nAChRs (27, 28, 30, 31, 45 (29, 30, 32, 43, 46, 47) . As illustrated in Fig. 2 , preor co-administration of nicotine, unlabeled 2FA, or cytisine with 2-[
18 F]FA dramatically reduces the accumulation of radioactivity in regions that have moderate-to-high densities of nAChRs. In the resulting images, the distribution of radioactivity is nearly random. The patterns of distribution of radioactivity in the human and non-human primate brain are very similar, and both correspond to the distribution and densities of nAChRs. Taken together, the results indicate that the accumulation of radioactivity in the human brain reflects specific binding of the radioligand to nAChRs. Quantitative studies with 2-[
18 F]FA, including those in which its specific binding in the human brain is blocked by nicotine, are a subject of future research.
Dosimetry
As evident from the whole-body distribution of radioactivity (Fig. 3) , organs receiving the greatest radiation exposure were the urinary bladder wall, liver, and kidneys. After bolus administration of 2-[ 18 F]FA to research participants, 89-93% of the administered dose was eliminated from the body in the urine (Fig. 4) . The biological half-life of the radioactivity calculated from the urine data was 4.0 ± 0.3 h (mean ±SD). The clearance of radioactivity from the blood plasma was closely approximated by the sum of three exponential functions. The terminal half-life of the plasma radioactivity, derived from the slowest exponential was 4.1 ± 0.3 h (mean ±SD), which is in good agreement with the biological half-life calculated from the urine data.
The concentration of radioactivity in any organ, except the urinary bladder and kidneys, never exceeded that in the liver at any time up to 7 h after the injection (Fig. 3) . This observation suggests that all other organs in the human body received radiation doses from their own radioactivity that were smaller than that received by the liver from its radioactivity.
To calculate estimates of radiation doses, we used the residence time for the urinary bladder contents (based on the accumulation of radioactivity in the urine) and residence times for seven organs that could be visualized or identified from their anatomical location (kidneys, liver, muscles, red marrow, trabecular and cortical bones, and brain).
Due to the low concentration of radioactivity in most organs, especially at later time points, their identification on the PET images was difficult. Therefore, to avoid an underestimation of the radiation dose estimates, especially in the values for whole-body effective dose (ED) and effective dose equivalent (EDE), we chose the most conservative approach for our calculations. Namely, to calculate residence times for all organs, except the urinary bladder, kidneys, liver, muscles, red marrow, trabecular and cortical bones, and brain, we assumed that their concentrations of radioactivity were equal to that in the liver at all time points. It should be noted that this approach resulted in some overestimation of radiation exposure to the body, as evidenced by the fact that the sum of residence times for all organs (3.3 ± 0.3 h) calculated without voiding exceeded the theoretical residence time for 18 F (2.6 h) by 25%.
As shown in Table 1 , even with this assumption, which results in an overestimation of radiation doses to the remaining organs, the radiation doses to these organs, as well as the whole-body ED and whole-body EDE, were reasonably low. The urinary bladder wall is the critical organ limiting the dose of 2-[ 18 F]FA that can be administered to humans. The radiation dose estimates for any other organ were less than one-third that to the urinary bladder wall. These findings are consistent with our previous observations in mice and monkeys showing that the urinary bladder receives the greatest radiation dose (unpublished data).
To calculate the radiation doses shown in Table 1 , we used a dynamic bladder model and a 2.4 h voiding interval. Utilization of a 1 h voiding period resulted in an absorbed dose equivalent for the urinary bladder wall (critical organ) of less than half that calculated for a 2.4 h voiding period (80 ± 14 µSv/MBq and 180 ± 30 µSv/MBq for 1 h and 2.4 h voiding intervals, respectively). Therefore, frequent voiding or/and stimulating voiding by encouraging water consumption or by intravenous hydration is recommended for decreasing the exposure to the bladder.
The results of the present study predict that multiple studies (up to four per year) by using a bolus administration of 2.6 MBq/kg (0.071 mCi/kg) of 2-[
18 F]FA per study could be performed on a single subject without exceeding the limits imposed by FDA regulations for human use of a "radioactive research drug" (21 CFR 361.1). It is expected that such a dose would be sufficient to calculate total volumes of distribution for most brain regions. Continued study will likely provide a more accurate estimation of the radiation dose to each organ and greater knowledge of the variability of the radiation dose to the urinary bladder wall among individuals. The results of these further studies may show that a higher dose of 2-[
18 F]FA could be used in humans without exceeding the radiation dose limit.
Safety
Our preclinical studies suggested that a mass dose of 2-[
18 F]FA of 10 pmol/kg or less should be non-toxic, as this dose is less than 1/2000 th the minimal dose causing a pharmacological effect in mice, rats, or monkeys (data not shown). In the present study, research participants received 1.6 ± 0.07 MBq/kg (0.043 ± 0.002 mCi/kg; mean ± SEM) of 2-[
18 F]FA as an i.v. bolus. The specific activity of the radioligand at the time of administration ranged from 210 to 1100 GBq/µmol (5.6 to 30.0 Ci/µmol). Therefore, the injected mass dose of 2-[ 18 F]FA varied from 1.3 to 10 pmol/kg (5 ± 2 pmol/kg, mean ± SEM). The participants reported feeling no drug effect, and no significant changes from baseline values for any cardiovascular parameter (i.e., heart rate, respiratory rate, blood pressure, ECG) were observed from the time of injection up to 24 h post-injection, the time when the participants left the NIDA research facilities.
In conclusion, the results of the present study demonstrate that 2-[
18 F]FA is suitable for visualizing binding to nAChRs in the human brain with PET at radioligand doses that produce radiation exposures within the guidelines set by the FDA for research studies in adults. Furthermore, our data indicate that up to four 2-[
18 F]FA injections of 185 MBq/70 kg (5 mCi/70 kg) each could be given to a single research volunteer within FDA guidelines. Taken together our findings suggest that 2-[ 18 F]FA will have utility in quantitative imaging of thalamic nAChRs and might be useful for studying these receptors in other brain regions. Data, which were calculated by using a dynamic bladder model with a 2.4 h voiding interval, are given as means ± SD for the number of participants in parentheses. In this figure, white represents the greatest accumulation of radioactivity, followed by red, yellow, and green, with blue representing the least accumulation. Although the greatest accumulation of radioactivity was in the thalamus, consistent with in vivo data from Rhesus monkeys and mice, the midbrain, pons, and cerebellum also accumulated sufficient radioactivity for visualization. The cortex, especially frontal areas, and striatum (putamen and caudate) accumulated moderate levels of radioactivity. h (right) after the injection. Each scan set contained 8-9 overlapping 15.5 cm fields of view, which surveyed the body from the top of the head to mid-thigh. The time required for each of these whole-body acquisitions ranged from 1.5 to 2.5 h. The scale represents actual radioactivity in the organs at the time of the scan acquisition. The greatest concentration of radioactivity was observed in the bladder. The organs that accumulated the next greatest concentration of radioactivity were the liver and kidneys. 
